Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies.</li><li> The company announced its 2Q2025 preliminary financial results.</li><li> The company continues to execute at a high level but faces reimbursement uncertainty.</li></ul>

BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The company announced its 2Q2025 preliminary financial results. The company continues to execute at a high level but faces reimbursement uncertainty.

New Zealand Professional Investment Services Firm, Forsyth Barr

Forsyth Barr

New Zealand Professional Investment Services Firm

We are proud to be a New Zealand owned firm, with 21 offices throughout the country and over 300 employees. We assist personal, institutional and corporate clients providing a full range of investment services.

Forsyth Barr is a foundation New Zealand Exchange firm (NZX) and accredited market participant. We have been confirmed by the Financial Markets Authority as a Qualifying Financial Entity (QFE).

Research is the cornerstone of our advice. We have one of New Zealand's leading teams of analysts. Our global affiliations ensure comprehensive research coverage of all major investment markets.

<ul><li>The a2 Milk Company (ATM) result was strong, with NPAT ~+7% ahead of consensus and little to fault within the mix.</li><li>ATM also announced the launch into the NZ$8bn China paediatric supplements category, with the launch of its China label (a2 Zhi Yi) range.</li><li>We would characterise the result as having very little for the bears and plenty for the bulls to layer growth expectations on.</li></ul>

The a2 Milk Company (ATM) result was strong, with NPAT ~+7% ahead of consensus and little to fault within the mix.ATM also announced the launch into the NZ$8bn China paediatric supplements category, with the launch of its China label (a2 Zhi Yi) range.We would characterise the result as having very little for the bears and plenty for the bulls to layer growth expectations on.

The A2 Milk Company 1H26 Result—Growing The Family

<ul><li>BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies.</li><li> The company announced its 1Q2025 preliminary financial results.</li><li> The company continues to execute at a high level by posting record 1Q revenue and continued growth in earnings.</li></ul>

BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The company announced its 1Q2025 preliminary financial results. The company continues to execute at a high level by posting record 1Q revenue and continued growth in earnings.

<ul><li>BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies.</li><li> The company announced its 4Q and full year 2024 results.</li><li> The company continues to execute at a high level by posting record revenue and earnings that beat expectations.</li></ul>

BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The company announced its 4Q and full year 2024 results. The company continues to execute at a high level by posting record revenue and earnings that beat expectations.

BSEM: Revenue and Earnings Blow Away Estimates

United States

BioStem Technologies, Inc. is a regenerative medicine company. The Company focuses on the stem cell industry for treatment in a range of rare and common degenerative diseases.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

BioStem Technologies (BSEM US)

BSEM: Company Meeting Challenges Head On

BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and...

Zacks Small Cap Research

The A2 Milk Company 1H26 Result—Growing The Family

ATM also announced the launch into the NZ$8bn China paediatric supplements category, with the launch of its China label (a2 Zhi Yi) range.

Forsyth Barr

BSEM: Growth Continues to Impress

BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and...

Zacks Small Cap Research

BSEM: Growth Continues to Impress

BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and...

Zacks Small Cap Research

BSEM: Revenue and Earnings Blow Away Estimates

BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)